209 related articles for article (PubMed ID: 30811933)
41. Evaluation of sequence variability in HIV-1 gp41 C-peptide helix-grafted proteins.
Tennyson RL; Walker SN; Ikeda T; Harris RS; McNaughton BR
Bioorg Med Chem; 2018 Mar; 26(6):1220-1224. PubMed ID: 28811070
[TBL] [Abstract][Full Text] [Related]
42. Altered bystander apoptosis induction and pathogenesis of enfuvirtide-resistant HIV type 1 Env mutants.
Garg H; Joshi A; Blumenthal R
AIDS Res Hum Retroviruses; 2009 Aug; 25(8):811-7. PubMed ID: 19619009
[TBL] [Abstract][Full Text] [Related]
43. Design and Biological Evaluation of
Meng G; Pu J; Li Y; Han A; Tian Y; Xu W; Zhang T; Li X; Lu L; Wang C; Jiang S; Liu K
J Med Chem; 2019 Oct; 62(19):8773-8783. PubMed ID: 31513410
[TBL] [Abstract][Full Text] [Related]
44. Discovery and optimization of a natural HIV-1 entry inhibitor targeting the gp41 fusion peptide.
Münch J; Ständker L; Adermann K; Schulz A; Schindler M; Chinnadurai R; Pöhlmann S; Chaipan C; Biet T; Peters T; Meyer B; Wilhelm D; Lu H; Jing W; Jiang S; Forssmann WG; Kirchhoff F
Cell; 2007 Apr; 129(2):263-75. PubMed ID: 17448989
[TBL] [Abstract][Full Text] [Related]
45. A RhoA-derived peptide inhibits human immunodeficiency virus-1 entry in vitro.
Maselko M; Ward C; Pastey M
Curr HIV Res; 2011 Jan; 9(1):1-5. PubMed ID: 21198428
[TBL] [Abstract][Full Text] [Related]
46. Potent HIV fusion inhibitors against Enfuvirtide-resistant HIV-1 strains.
He Y; Cheng J; Lu H; Li J; Hu J; Qi Z; Liu Z; Jiang S; Dai Q
Proc Natl Acad Sci U S A; 2008 Oct; 105(42):16332-7. PubMed ID: 18852475
[TBL] [Abstract][Full Text] [Related]
47. Genetic Pathway of HIV-1 Resistance to Novel Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Xiong S; Qiao Y; Qiu Z; He Y
J Virol; 2015 Dec; 89(24):12467-79. PubMed ID: 26446597
[TBL] [Abstract][Full Text] [Related]
48. A Peptide-Based HIV-1 Fusion Inhibitor with Two Tail-Anchors and Palmitic Acid Exhibits Substantially Improved In Vitro and Ex Vivo Anti-HIV-1 Activity and Prolonged In Vivo Half-Life.
Su S; Rasquinha G; Du L; Wang Q; Xu W; Li W; Lu L; Jiang S
Molecules; 2019 Mar; 24(6):. PubMed ID: 30901967
[TBL] [Abstract][Full Text] [Related]
49. HIV-1 inhibitory properties of eCD4-Igmim2 determined using an Env-mediated membrane fusion assay.
Yang E; Gardner MR; Zhou AS; Farzan M; Arvin AM; Oliver SL
PLoS One; 2018; 13(10):e0206365. PubMed ID: 30359435
[TBL] [Abstract][Full Text] [Related]
50. A Lipopeptide HIV-1/2 Fusion Inhibitor with Highly Potent
Chong H; Xue J; Xiong S; Cong Z; Ding X; Zhu Y; Liu Z; Chen T; Feng Y; He L; Guo Y; Wei Q; Zhou Y; Qin C; He Y
J Virol; 2017 Jun; 91(11):. PubMed ID: 28356533
[TBL] [Abstract][Full Text] [Related]
51. Discovery of entry inhibitors for HIV-1 via a new de novo protein design framework.
Bellows ML; Taylor MS; Cole PA; Shen L; Siliciano RF; Fung HK; Floudas CA
Biophys J; 2010 Nov; 99(10):3445-53. PubMed ID: 21081094
[TBL] [Abstract][Full Text] [Related]
52. The M-T hook structure is critical for design of HIV-1 fusion inhibitors.
Chong H; Yao X; Sun J; Qiu Z; Zhang M; Waltersperger S; Wang M; Cui S; He Y
J Biol Chem; 2012 Oct; 287(41):34558-68. PubMed ID: 22879603
[TBL] [Abstract][Full Text] [Related]
53. Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X; Zhang X; Chong H; Zhu Y; Wei H; Wu X; He J; Wang X; He Y
J Virol; 2017 Sep; 91(18):. PubMed ID: 28659478
[TBL] [Abstract][Full Text] [Related]
54. HIV-1 variants with a single-point mutation in the gp41 pocket region exhibiting different susceptibility to HIV fusion inhibitors with pocket- or membrane-binding domain.
Lu L; Tong P; Yu X; Pan C; Zou P; Chen YH; Jiang S
Biochim Biophys Acta; 2012 Dec; 1818(12):2950-7. PubMed ID: 22867851
[TBL] [Abstract][Full Text] [Related]
55. Development of HIV-1 fusion inhibitors targeting gp41.
Lu K; Asyifah MR; Shao F; Zhang D
Curr Med Chem; 2014 Jun; 21(17):1976-96. PubMed ID: 24350848
[TBL] [Abstract][Full Text] [Related]
56. Massively Parallel Profiling of HIV-1 Resistance to the Fusion Inhibitor Enfuvirtide.
Dingens AS; Arenz D; Overbaugh J; Bloom JD
Viruses; 2019 May; 11(5):. PubMed ID: 31096572
[TBL] [Abstract][Full Text] [Related]
57. Targeting the sticky fingers of HIV-1.
Blumenthal R; Dimitrov DS
Cell; 2007 Apr; 129(2):243-5. PubMed ID: 17448985
[TBL] [Abstract][Full Text] [Related]
58. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
Pan C; Lu H; Qi Z; Jiang S
AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
[TBL] [Abstract][Full Text] [Related]
59. An insight on the leading HIV entry inhibitors.
Veiga AS; Santos NC; Castanho MA
Recent Pat Antiinfect Drug Discov; 2006 Jan; 1(1):67-73. PubMed ID: 18221135
[TBL] [Abstract][Full Text] [Related]
60. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.
Ashkenazi A; Viard M; Unger L; Blumenthal R; Shai Y
FASEB J; 2012 Nov; 26(11):4628-36. PubMed ID: 22872679
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
